Success Story: Iranian Researcher Earns NIW Approval for Advancing Women’s Health and Cancer Prevention
Client’s Testimonial:
“I’m deeply grateful for the professional guidance and support throughout my NIW journey. Their expertise made the entire process smooth and successful.”
On October 16th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Researcher in the field of Gynecologic Oncology (Approval Notice).
General Field: Gynecologic Oncology
Position at the Time of Case Filing: Researcher
Country of Origin: Iran
Country of Residence at the Time of Filing: Iran
Approval Notice Date: October 16th, 2025
Processing Time: 1 year, 6 months, 1 day
Case Summary:
We are pleased to share the NIW approval of a researcher from Iran whose work advances women’s health through improved prevention, diagnosis, and treatment of gynecologic cancers. At the time of filing, she was conducting research that bridges clinical medicine and public health, with the goal of reducing cancer mortality and improving evidence-based healthcare policy. With a strong record of publications, citations, and expert endorsements, she presented an exceptional case for NIW approval.
Research with National Importance
The client’s research focuses on gynecologic cancers, including cervical, ovarian, and vulvar cancers, to identify risk factors and optimize clinical outcomes. Her findings inform treatment strategies and preventive care policies that support early detection and equitable access to women’s healthcare. As these diseases remain a leading cause of mortality among American women, her work directly aligns with U.S. public health priorities in cancer prevention and women’s wellness.
Academic Achievements and Recognition
The client holds an M.D. specializing in gynecologic oncology and has authored 15 peer-reviewed journal articles and one conference abstract in leading outlets such as Psychology, Health & Medicine, Indian Pediatrics, and the Iranian Journal of Reproductive Medicine. Her research has been cited 153 times by independent scholars, with two papers ranking among the top 20% most cited in Clinical Medicine. Her studies on ectopic pregnancy, intimate partner violence, and vulvar cancer epidemiology have informed both clinical practice and medical research, underscoring her impact in women’s health.
Expert Endorsements
Independent experts praised her scientific and clinical contributions.
One recommender wrote:
“The United States must recognize and support [client]’s research, as she is an invaluable medical research community member with a steady history of achievement and valuable contribution to our field.”
This statement underscores her long-standing commitment to advancing women’s health and her continued value to the U.S. medical research community.
NIW Approval and Outlook
The I-140 NIW petition was filed on April 15, 2024, received an RFE on March 4, 2025, and was approved on October 16, 2025. USCIS recognized her publication record, citation impact, and the national significance of her work as meeting the NIW standard.
With NAILG’s support, the client achieved NIW approval and continues her efforts to expand access to equitable, evidence-based care for women worldwide. Her ongoing research will strengthen U.S. healthcare innovation and reinforce leadership in gynecologic oncology and women’s health.